Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Inclusion Criteria: * Histologically or cytologically confirmed metastatic melanoma * Stage IV or unresectable stage III disease * Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral computed tomography (CT) scan * No known brain metastases * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60-100% * Life expectancy \> 12 weeks * White blood cell (WBC) ≥ 3,000/mcL * Absolute neutrophil count (ANC) ≥ 1,500/mcL * Platelet count ≥ 100,000/mcL * Hemoglobin ≥ 9 g/dL * Total bilirubin normal * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal * Creatinine normal OR creatinine clearance ≥ 60 mL/min * Proteinuria ≤ 1+ by dipstick OR 24-hour urine protein ≤ 1 g * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception prior to study until completion of study treatment * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD0530 * No QTc prolongation (defined as a QTc interval ≥ 480 msecs) or other significant electrocardiogram (ECG) abnormalities * No poorly controlled hypertension (e.g., systolic blood pressure \[BP\] of ≥ 140 mm Hg or diastolic BP of ≥ 90 mm Hg) * No condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation), prior surgical procedures affecting absorption, or active peptic ulcer disease that impairs the ability to swallow AZD0530 tablets * No intercurrent cardiac dysfunction including, but not limited to, any of the following: * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * No recent history of ischemic heart disease including myocardial infarction * No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements * No other malignancy within the past 5 years, except definitively treated, localized, nonmelanoma skin cancer or low-grade cervical neoplasm * At least 4 weeks since prior and no more than one prior treatment regimen for advanced disease * No prior kinase inhibitor with activity against Src kinases for metastatic melanoma * More than 4 weeks since prior luteinizing hormone-releasing hormone agonists * No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients * No concurrent prohibited cytochrome P450 3A4 (CYP3A4)-active agents or substances * Prohibited drugs should be discontinued 7 days prior to the administration of the first dose of AZD0530 and for 7 days following discontinuation of AZD0530 * No other concurrent investigational agents or commercial therapies